IGIB inks MoU with TATA Sons for COVID-19 detection assay

May 08, 2020 | Friday | News

FELUDA for COVID-19 has been designed for mitigating the ongoing COVID-19 situation and cater to mass testing

Image credit- shutterstock.com

Image credit- shutterstock.com

New Delhi based CSIR- Institute of Genomics and Integrative Biology (CSIR-IGIB) and Mumbai based TATA Sons have signed a MoU for licensing of knowhow for FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) for rapid diagnosis of COVID-19

The license shall include transfer of the knowledge for scaling up the KNOWHOW in the form of a kit that can be deployed for COVID-19 testing on ground as early as end of May.

A completely indigenous scientific invention, FELUDA for COVID-19 has been designed for mitigating the ongoing COVID-19 situation and cater to mass testing. Its main advantages are its affordability, relative ease of use and non-dependency on expensive Q-PCR machines. CSIR IGIB and TATA Sons will now work together to bring it for widespread use at the earliest.

Dr Anurag Agrawal, Director-IGIB highlighted that the technology was conceived and developed at CSIR IGIB under sickle cell mission and utilizes an indigenously developed cutting edge CRISPR Cas9 technology to specifically recognize COVID-19 sequence in a sample. A combination of CRISPR biology and paper-strip chemistry leads to a visible signal readout on a paper strip that can be rapidly assessed for establishing the presence of viral infection in a sample.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy